The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.

Hertzer LA, Siegel RM, Kharofa RY, Stackpole KM, Mahabee-Gittens EM

Childhood obesity (Print)9 Jan 2026Cited by 1 (Europe PMC)

PMID41715277DOI10.1177/21532176251413898PepBankPUB-41715277

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists, including liraglutide, had a significant BMI treatment effect of -1.7.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including liraglutide reduced BMI by 1.7.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
BMI treatment effect
−1.7
pooled GLP-1 receptor agonists; unit not stated
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4171527701
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists, including liraglutide, had a significant ALT treatment effect of -3.0.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including liraglutide lowered ALT by 3.0.
Peptide
Liraglutide
Outcome
DecreaseAlanine aminotransferase
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Measurements
ALT treatment effect
−3
pooled GLP-1 receptor agonists; unit not stated
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
4 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
Summary · context
The clinical significance of the ALT decreases remains uncertain and warrants further examination in future trials.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4171527702
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists, including semaglutide, had a significant BMI treatment effect of -1.7.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including semaglutide reduced BMI by 1.7.
Peptide
Semaglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
BMI treatment effect
−1.7
pooled GLP-1 receptor agonists; unit not stated
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4171527703
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists, including semaglutide, had a significant ALT treatment effect of -3.0.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including semaglutide lowered ALT by 3.0.
Peptide
Semaglutide
Outcome
DecreaseAlanine aminotransferase
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Measurements
ALT treatment effect
−3
pooled GLP-1 receptor agonists; unit not stated
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
4 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
Summary · context
The clinical significance of the ALT decreases remains uncertain and warrants further examination in future trials.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4171527704
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists including liraglutide had no significant treatment effect on high-density lipoprotein.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including liraglutide did not significantly change HDL.
Peptide
Liraglutide
Outcome
No significant changeHigh-density lipoprotein
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4171527705
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists including liraglutide had no significant treatment effect on low-density lipoprotein.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including liraglutide did not significantly change LDL.
Peptide
Liraglutide
Outcome
No significant changeLow-density lipoprotein
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4171527706
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists including liraglutide had no significant treatment effect on hemoglobin A1c.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including liraglutide did not significantly change HbA1c.
Peptide
Liraglutide
Outcome
No significant changeHemoglobin A1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4171527707
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists including semaglutide had no significant treatment effect on high-density lipoprotein.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including semaglutide did not significantly change HDL.
Peptide
Semaglutide
Outcome
No significant changeHigh-density lipoprotein
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4171527708
09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists including semaglutide had no significant treatment effect on low-density lipoprotein.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including semaglutide did not significantly change LDL.
Peptide
Semaglutide
Outcome
No significant changeLow-density lipoprotein
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4171527709
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In youths with obesity, pooled GLP-1 receptor agonists including semaglutide had no significant treatment effect on hemoglobin A1c.
In plain wordsIn youths with obesity, pooled GLP-1 drugs including semaglutide did not significantly change HbA1c.
Peptide
Semaglutide
Outcome
No significant changeHemoglobin A1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Only BMI (-1.7, p = 0.02) and ALT (-3.0, p = 0.01) showed a significant treatment effect.
3 context sentences(design, population, supporting numbers)
Summary · context
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower body mass index (BMI) in youths with obesity, less is known about their effect on metabolic parameters such as alanine aminotransferase (ALT), high-density lipoprotein, low-density lipoprotein, and hemoglobin A1c levels.
Summary · context
A search of the PubMed, Scopus, and Embase databases was conducted with variations of the terms GLP-1, obesity, semaglutide, exenatide, liraglutide, randomized clinical trial, adolescent, youth, and children.
Summary · context
Four studies focused on exenatide, one on semaglutide, and one on liraglutide, with participant numbers ranging from 11 to 201 and study lengths of 12 to 68 weeks.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4171527710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.